Diabetes: Medical Equipment
The question
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure alignment of Integrated Care Boards with NICE guideline 28, updated in 2022, related to the fair and equitable adoption of continuous glucose monitoring for eligible people with type 2 diabetes.
Answered by Andrew Gwynne
The National Institute for Health and Care Excellence recommended that all people living with type 1 diabetes and people living with type 2 diabetes who required insulin therapy should be eligible for real time continuous glucose monitoring (CGM). The guidance recommends that all adults and children with type 1 diabetes are eligible for CGM, and that only certain adult and child populations with type 2 diabetes are eligible for CGM.
NHS England is developing new reporting systems which are designed to support ICBs to monitor the delivery of CGM. Data on CGM for diabetics is now collected as part of the National Diabetes Audit (NDA). NHS England plans to routinely publish this data in the NDA Core Quarterly dashboard in 2025/26, which will provide the data insights ICBs require, including data on CGM uptake, variation, and health inequalities.
This information will help in providing ICBs with data about inequalities and diabetes, and will allow them and NHS England to target strategies to ensure uptake of those patients who are clinically eligible for CGM, but where there are wider factors limiting access to support.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →